Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC): The Immune and IGFR Pathways

被引：0
|
作者：
Penault-Llorca, F.
Abrial, C.
Douplat, M-M
Privat, M.
Uhrhammer, N.
Desrichard, A.
Bidet, Y.
Radosevic-Robin, N.
Cayre, A.
Aube, C.
Kwiatkowski, F.
Bignon, Y-J
Chollet, P.
Nabholtz, J-M
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Auvergne, EA 4677 ERTICa, Clermont Ferrand, France
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
254
引用
收藏
页码：63A / 63A
页数：1
相关论文
共 50 条
  • [41] Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells
    Phuoc Vinh Nguyen
    Herve-Aubert, Katel
    David, Stephanie
    Lautram, Nolwenn
    Passirani, Catherine
    Chourpa, Igor
    Aubrey, Nicolas
    Allard-Vannier, Emilie
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2020, 157 : 74 - 84
  • [42] Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer
    Anborgh, Pieter H.
    Lee, Danny J.
    Stam, Pieter F.
    Tuck, Alan B.
    Chambers, Ann F.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (08) : 727 - 734
  • [43] Prediction of treatment responses to neoadjuvant chemotherapy in triple -negative breast cancer by analysis of immune checkpoint protein expression
    Asano, Y.
    Kashiwagi, S.
    Goto, W.
    Morisaki, T.
    Noda, S.
    Takashima, T.
    Onoda, N.
    Hirakawa, K.
    CANCER RESEARCH, 2016, 76
  • [44] Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer
    Wang, Xiaoping
    Matsuda, Naoko
    Lim, Bora
    Krishnamurthy, Savitri
    Song, Juhee
    Shen, Yu
    Wu, Wenhui
    Hu, Jianhua
    Woodward, Wendy A.
    Reuben, James M.
    Lucci, Anthony
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers
    Zhou, Zijian
    Elshafeey, Nabil A.
    Rauch, David E.
    Adrada, Beatriz E.
    Candelaria, Rosalind P.
    Guirguis, Mary S.
    Yang, Wei
    Boge, Medine
    Mohamed, Rania M.
    Whitman, Gary J.
    Lane, Deanna L.
    Le-Petross, Huong C.
    Leung, Jessica W. T.
    Santiago, Lumarie
    Scoggins, Marion E.
    Spak, David A.
    Patel, Miral M.
    Perez, Frances
    Tripathy, Debu
    Valero, Vicente
    Yam, Clinton
    Moulder, Stacy
    White, Jason B.
    Son, Jong Bum
    Pagel, Mark D.
    Ma, Jingfei
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.
    Smit, Teresa
    Rapoport, Bernardo Leon
    Steel, Helen C.
    Benn, Carol
    Nayler, Simon
    Heyman, Liezl
    Theron, Annette J.
    Hlatswayo, Nomsa
    Kwofie, Luyanda Li
    Meyer, Pieter
    Anderson, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
    Yam, Clinton
    Yen, Er-Yen
    Chang, Jeffrey T.
    Bassett, Roland L., Jr.
    Alatrash, Gheath
    Garber, Haven
    Huo, Lei
    Yang, Fei
    Philips, Anne, V
    Ding, Qing-Qing
    Lim, Bora
    Ueno, Naoto T.
    Kannan, Kasthuri
    Sun, Xiangjie
    Sun, Baohua
    Cuentas, Edwin Roger Parra
    Symmans, William Fraser
    White, Jason B.
    Ravenberg, Elizabeth
    Seth, Sahil
    Guerriero, Jennifer L.
    Rauch, Gaiane M.
    Damodaran, Senthil
    Litton, Jennifer K.
    Wargo, Jennifer A.
    Hortobagyi, Gabriel N.
    Futreal, Andrew
    Wistuba, Ignacio I.
    Sun, Ryan
    Moulder, Stacy L.
    Mittendorf, Elizabeth A.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5365 - 5375
  • [48] Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer.
    Levee, Alexis
    Wong, Megan
    Flores, Sarah
    Ruel, Nora H.
    Lavasani, Sayeh Moazami
    Patel, Niki
    Sedrak, Mina S.
    Stewart, Daphne B.
    Waisman, James Ross
    Yuan, Yuan
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Hall, C.
    Hess, R.
    Ravenberg, L.
    Clayborn, A.
    Rauch, G. M.
    Candelaria, R.
    Mittendorf, E. A.
    Moulder, S. L.
    Thompson, A.
    Lucci, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study.
    Gamucci, Teresa
    Mentuccia, Lucia
    Vici, Patrizia
    Iezzi, Laura
    Sperduti, Isabella
    Astone, Antonio
    Marchetti, Paolo
    Pizzuti, Laura
    Michelotti, Andrea
    Sini, Valentina
    Cassano, Alessandra
    Ciancola, Fabrizio
    Moscetti, Luca I.
    Quadrini, Silvia
    Landucci, Elisabetta
    Magnolfi, Emanuela
    Sergi, Domenico
    Natoli, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345